FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling

The U.S. Federal Trade Commission (FTC) has secured a significant antitrust victory after a federal judge ruled to block Edwards Lifesciences’ proposed acquisition of JenaValve Technology, according to court records released Friday. The decision marks a major development in U.S. healthcare merger enforcement and highlights heightened regulatory scrutiny of consolidation in the medical device industry.

The FTC filed its lawsuit in August, arguing that the acquisition would substantially reduce competition in the market for transcatheter aortic valve replacement (TAVR) systems designed to treat aortic regurgitation. This potentially fatal heart condition occurs when the aortic valve fails to close properly, allowing blood to leak backward into the heart. Regulators emphasized that Edwards Lifesciences and JenaValve are currently the only two companies in the United States conducting clinical trials for TAVR devices specifically targeting aortic regurgitation, making the deal especially concerning from a competition standpoint.

FTC spokesperson Joe Simonson described the ruling as “a major win for the Trump-Vance administration,” adding that the agency remains committed to promoting innovation, lowering healthcare costs, and protecting patient access to life-saving medical technologies. The FTC has increasingly positioned itself as a watchdog against mergers it believes could limit innovation or raise prices in critical healthcare markets.

U.S. District Judge Rudolph Contreras, based in Washington, granted the FTC’s request to block the transaction. While the ruling itself is public, the detailed opinion explaining the court’s reasoning will remain sealed temporarily, allowing the companies to submit a redacted version that safeguards confidential business information.

In response, Edwards Lifesciences announced late Friday that it will not move forward with the acquisition, though it strongly disagreed with the court’s decision. The company stated that it believes the deal would have benefited a large and underserved patient population in need of advanced treatment options for aortic regurgitation.

Despite the legal setback, Edwards Lifesciences also shared positive financial news, raising its full-year 2026 adjusted earnings per share forecast. The company now expects earnings between $2.90 and $3.05 per share, up from its previous guidance of $2.80 to $2.95. Edwards remains a dominant player in the TAVR market, with its flagship system for aortic stenosis generating $1.15 billion in revenue during the third quarter, underscoring its strong market position even as regulatory pressures intensify.